STENDINIAI PRANEŠIMAI. Sulforaphane prolongs survival after experimental kidney transplantation
Europos urologų asociacijos 205-asis suvažiavimas, Barselona, 2010
Sulforaphane prolongs survival after experimental kidney transplantation
Cekauskas, A.1, Manikas, M.2, Bruns, H.2, Mohr, E.2, Nickkholgh, A.2, Herr, I.2, Gross, M.L.3, Zorn, M.4, Jankevicius, F.5, Strupas, K.6, Büchler, M.W.2, Schemmer, P.2
1Ruprecht-Karls-University, Dept. of General Surgery, Vilnius, Lithuania, 2Ruprecht-Karls-University, Dept. of General Surgery, Heidelberg, Germany, 3Ruprecht-Karls-University, Dept. of Pathology, Heidelberg, Germany, 4Ruprecht-Karls-University, Dept. of Internal Medicine, Heidelberg, Germany, 5Vilnius University Hospital Santariskiu Clinics, Dept. of Urology, Vilnius, Lithuania, 6Vilnius University Hospital Santariskiu Clinics, Dept. of Abdominal Surgery, Vilnius, Lithuania
Introduction & Objectives: Izothiocyonate sulforaphane (SFN) is an antioxidative, anti-inflammatory and chemopreventive agent. This study was designed to investigate its effect on ischemia/reperfusion injury after experimental kidney transplantation (KTx).
Conclusions: Data presented here clearly demonstrate for the first time that sulforaphane protects kidney grafts from ischemia/reperfusion injury through its anti-oxidative effect, preserving the mitochondrial microstructure and prolonging graft survival.